Cardionate, solution for injection 100mg/ml 5ml ampoules 10pcs

Composition

Per ampoule:

Active ingredient:  

Meldonium dihydrate (trimethylhydrazinium propionate dihydrate) in terms of dihydrate without adsorbed moisture-500 mg;

Auxiliary substances:  

Water for injection-5 ml

Pharmacological action

Cardionate has a metabolic, cardioprotective, antianginal, antihypoxic, adaptogenic, improving cerebral circulation effect.

Indications

In complex therapy: coronary heart disease (angina pectoris, myocardial infarction), chronic heart failure, cardialgia on the background of dyshormonal myocardial dystrophy.

In complex therapy: disorders of cerebral circulation (ischemic stroke, cerebrovascular insufficiency).

In complex therapy: acute retinal circulatory disorders, hemophthalmos and retinal hemorrhages of various etiologies, thrombosis of the central retinal vein and its branches, retinopathy of various etiologies (including diabetic and hypertensive) – only for parabulbar use.

Reduced working capacity, physical overexertion (including athletes).

Alcohol withdrawal syndrome (as part of complex specific therapy).

Use during pregnancy and lactation

During pregnancy and lactation (breastfeeding), the use of the drug is contraindicated.

Contraindications

Hypersensitivity to the drug; increased intracranial pressure (with impaired venous outflow and intracranial tumors); pregnancy, lactation, age up to 18 years.

Liver and/or kidney diseases should be treated with caution.

Side effects

From the cardiovascular system: rarely-tachycardia, changes in blood pressure.

From the central nervous system: rarely-psychomotor agitation.

From the digestive system: rarely-dyspeptic symptoms.

Allergic reactions: rarely – skin itching, redness, rash, swelling.

Interaction

When used together, meldonium enhances the effect of antianginal drugs, some antihypertensive drugs, and cardiac glycosides.

With the simultaneous use of meldonium with nitroglycerin, nifedipine, alpha-blockers, antihypertensive agents and peripheral vasodilators, moderate tachycardia and arterial hypotension may develop (caution is required with these combinations).

How to take, course of use and dosage

Due to the possible stimulating effect, the drug is recommended to be used in the first half of the day.

Angina pectoris and myocardial infarction (in combination therapy): intravenously (iv) 0.5-1 g (5-10 ml of a solution for injection of 100 mg/1 ml) 1 time a day, then switch to taking the drug inside.

Chronic heart failure (as part of combination therapy): iv 0.5-1 g (5-10 ml of solution for injection) 1 time a day: the course of treatment is 10-14 days, then switch to taking the drug inside.

Cardialgia on the background of dyshormonal myocardial dystrophy: iv 0.5-1 g (5-10 ml of solution for injection) 1 time a day or iv 0.5 g 1-2 times a day; the course of treatment is 10-14 days, then switch to taking the drug inside.

Cerebrovascular accident (as part of combination therapy): acute phase-iv 500 mg (5 ml solution for injection) 1 time a day for 10 days, then the transition to oral use is possible; chronic disorders of cerebral circulation’, iv 500 mg (5 ml solution for injection) 1 time a day; the course of treatment is 10-14 days, then the transition to oral use is possible.

Vascular pathology of the fundus and retinal dystrophy (in complex therapy): parabulbarno 0.5 ml of solution for injection for 10 days.

Physical and mental overload: iv 0.5 g (5 ml of solution for injection) 1 time a day; the course of treatment is 10-14 days. If necessary, the course is repeated in 2-3 weeks.

Alcohol withdrawal syndrome: IV 500 mg (5 ml of solution for injection) 2 times a day; the course of treatment is 7-10 days.

Overdose

Cases of cardionate overdose are not known.

The drug is low-toxic and does not cause side effects that are dangerous to the health of patients.

Description

A metabolic agent.

Description

Clear, colorless liquid.

Functional features

After intravenous use, the maximum concentration of the drug in the blood plasma is reached immediately after its use. There are no data on the bioavailability of the drug after intramuscular use. It is metabolized in the body with the formation of two main metabolites, which are excreted by the kidneys. The elimination half-life is 3 to 6 hours.

Complete set

Solution for injection of 100 mg / ml. 5 ml in ampoules of neutral glass. 5 ampoules are packed in a contour cell package made of polyvinyl chloride film. 1,2 contour cell packages together with the instructions for use and a knife for opening ampoules (in the case of ampoules with a point or a break-off ring, the knife is not inserted) in a cardboard pack.

Special instructions

The drug should be used with caution in patients with liver and/or kidney diseases, especially for a long time.

Long-term experience in the treatment of acute myocardial infarction and unstable angina in cardiology departments shows that meldonium is not a first-line drug for acute coronary syndrome and its use is not urgently needed.

Influence on the ability to drive vehicles and maintain other mechanisms

There are no data on the adverse effects of meldonium on the speed of psychomotor reactions.

Form of production

Solution for injection.

Storage conditions

At a temperature not exceeding 25°C. Keep out of reach of children.

Shelf

life is 3 years. Do not use after the expiration date indicated on the package.

Active ingredient

Meldonium

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection